NEW YORK, June 23, 2011 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that Radient Pharmaceuticals Corporation  (OTCQX: RXPC), the developer and worldwide marketer of the Onko-Sure® non-invasive cancer blood test kit, has qualified to trade on the OTC market's highest tier, OTCQX®.
"Radient Pharmaceuticals has chosen to remain investor-focused as they transition to trade on OTCQX, which allows them to continue to provide superior information and transparent trading on the quality-controlled OTCQX platform," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Radient Pharmaceuticals to OTCQX."
Radient Pharmaceuticals began trading today on the OTC market's prestigious tier, OTCQX U.S. Premier. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcqx.com  and www.otcmarkets.com .
"In moving to OTCQX, we will continue to deliver liquidity, transparency, and an efficient market for our shareholders while reducing the financial and management resources required for an exchange listing," Douglas MacLellan, CEO of Radient Pharmaceuticals. "We are moving forward, dedicating more time and resources to the execution of our core business delivering high-value cancer diagnostics to the global healthcare system."
Merriman Capital, Inc. will serve as Radient Pharmaceuticals' Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing guidance on OTCQX requirements.
About Radient Pharmaceuticals<